TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00287352

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olanzapine, Amantadine
Description: Olanzapine continuing as clinically indicated, Amantadine 100 mg tid

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Olanzapine and placebo
Description: Olanzapine continuing as clinically indicated
Study: NCT02229487

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oral glucose tolerance

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral glucose tolerance
Study: NCT02264301

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Puerarin injection 400 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Qingkailing injection 40 ml
Study: NCT01058876

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deuterated nicotine and cotinine
Description: used as a marker for pharmacokinetic studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deuterated nicotine and cotinine
Description: used as a marker for pharmacokinetic studies
Study: NCT01319305

Intervention type: DEVICE
Intervention: FinESS Sinus Treatment
Description: balloon sinuplasty
Study: NCT03543046

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tortle Midliner
Description: The Tortle Midliner will be applied in the treatment group within the first 3 hours of life and maintained until 72 hours of life.
Study: NCT03869684

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-0814
Description: Randomly assigned dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-0814
Description: Randomly assigned dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo manufactured to mimic MT-0814
Study: NCT04553731

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: empowerment program with mHealth
Description: empowerment program with mHealth
Study: NCT01170429

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Procaterol hydrochloride
Description: 25µg BID for 8 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Meptin placebo
Description: 25µg BID for 8 weeks
Study: NCT00778817

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMC-A12
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mitotane
Description: Given orally
Study: NCT03869684

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo manufactured to mimic MT-0814
Study: NCT02414074

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Youth Behavioral Intervention
Description: Teen Intervene is an early intervention program for 12-19 year olds.
Study: NCT02925481

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Moderate Online yoga participation
Description: Phase 1: Testing yoga videos for emotional regulation and self-compassion which will inform the selected videos for Phase 2 prescription Phase 2: 150 minutes of Online streaming yoga videos completed at home. Week 1/2 introductory videos that include short video clips breaking down each pose Weeks 3-12 increase in difficulty (all videos are appropriate for beginners)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stretching and toning
Description: Phase 1: Developing 12 week prescription for online control videos Phase 2: Online streaming stretching and toning videos completed at home which consist of a warm-up, 1 balance, 2 core, 2-3 upper body and lower body exercises, 6 stretches, cool-down

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low dose online yoga participation
Description: Phase 1: Testing yoga videos for emotional regulation and self-compassion which will inform the selected videos for Phase 2 prescription Phase 2: 60 minutes of Online streaming yoga videos completed at home. Week 1/2 introductory videos that include short video clips breaking down each pose Weeks 3-12 increase in difficulty (all videos are appropriate for beginners)
Study: NCT03374865

Intervention type: OTHER
Intervention: Facetalk
Description: Area of interest: communication during Facetalk consultations
Study: NCT02414074

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Parent Education
Description: Everyday Parenting is a parent training curriculum.
Study: NCT00720473

Intervention type: DRUG
Group type: OTHER
Intervention: Lamotrigine
Description: Lamotrigine with dosage range from 25 mg to 200 mg per day.
Study: NCT04403191

Intervention type: DRUG
Intervention: Ondansetron
Description: ondansetron 4 mg intravenous immediately once reached to I.C.U and another same dose after 6 hours while patients of group

Intervention type: DRUG
Intervention: isopropyl alcohol 70% inhalation
Description: inhalation every 15 min for 4 times then repeated after 6 hours

Intervention type: PROCEDURE
Intervention: laparoscopic appendectomy
Description: all patients received post operatively after laparoscopic appenectomy

Intervention type: PROCEDURE
Intervention: laparoscopic appendectomy
Description: all patients received post operatively after laparoscopic appenectomy

Intervention type: PROCEDURE
Intervention: laparoscopic appendectomy
Description: all patients received post operatively after laparoscopic appenectomy
Study: NCT04441801

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: stretching exercise
Description: Static stretching consists of stretching a muscle (or group of muscles) to its farthest point and then maintaining or holding that position

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: stretching exercise
Description: Static stretching consists of stretching a muscle (or group of muscles) to its farthest point and then maintaining or holding that position

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: stretching exercise
Description: Static stretching consists of stretching a muscle (or group of muscles) to its farthest point and then maintaining or holding that position

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: stretching exercise
Description: Static stretching consists of stretching a muscle (or group of muscles) to its farthest point and then maintaining or holding that position
Study: NCT03374865

Intervention type: OTHER
Intervention: Face-to-face consultation
Description: Area of interest: communication during face-to-face consultations
Study: NCT02571673

Intervention type: BEHAVIORAL
Intervention: Assessments
Description: Usability outcomes will come from patient surveys and interviews and a nurse practitioner interview in Aim 1: Part 1. In Aim 1: Part 2, patients and their primary care providers will complete online surveys regarding feasibility. Health outcomes and data regarding health care actions will be collected from HN-STAR and the clinic note will be collected to assess feasibility of collecting these metrics in a future trial. Directly after each clinic visit, the NP will complete one brief online survey for each participant.
Study: NCT02200822

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RAAS blockers
Description: RAAS blockers (combination of ACE-I/ARB and a mineralocorticoid receptor antagonist)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RAAS blockers
Description: RAAS blockers (combination of ACE-I/ARB and a mineralocorticoid receptor antagonist)
Study: NCT02756624

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC-170 0.24%

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AC-170 Vehicle
Study: NCT02783586

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Quadratus Lumborum Block type II
Description: Local anaesthetic injection on the posterior border of the quadratus lumborum muscle

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transversus Abdominalis Plane Block
Description: Local anaesthetic injection between internal oblique and transversus abdominis muscle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: 20 ml of bupivacaine with adrenaline

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: 20 ml of bupivacaine with adrenaline

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultraplex
Description: A non-stimulating echogenic single-shot needle designed for regional analgesia under ultrasound guidance.
Study: NCT04217031

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT00712660

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: antipsychotic dose increase
Description: 20% increase in the dose of current antipsychotic medication

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: no intervention
Description: Treatment as usual
Study: NCT04622618

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gabapentin
Description: Anticonvulsant, Antiemetic, Analgesic
Study: NCT03799757

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 40ml of 0.25% bupivacaine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 40ml of 0.9% normal saline
Study: NCT04977089

Intervention type: DIAGNOSTIC_TEST
Intervention: lipid profile test .
Description: Assesment of lipid profile of patients (cholesterol level ,TG ,VLDL )
Study: NCT04530188

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Description: Inhaled sedation with sevoflurane using the Anesthesia Conserving Device (AnaConDa-S, Sedana Medical, Danderyd, Sweden)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Intravenous sedation with propofol, as already used in our ICU
Study: NCT03207815

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgotinib
Description: Tablet(s) administered orally
Study: NCT00840788

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: octyl-2-cyanoacrylate adhesive glue
Description: use of octyl-2-cyanoacrylate adhesive glue for perineal skin repair after episiotomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Subcuticular suture of perineal skin
Description: Use of continuous subcuticular suture with rapidly absorbable polyglactin 910 for closure of the perineal skin in episiotomy repair
Study: NCT04768491

Intervention type: DRUG
Intervention: Dacomitinib
Description: effectiveness and safety profile in patients with EGFR mutation-positive advanced NSCLC treated with dacomitinib (Vizimpro®) as the first-line treatment followed by 3rd generation EGFR-TKI in case the T790M resistance mutation was developed.
Study: NCT03207815

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to match filgotinib
Description: Tablet(s) administered orally
Study: NCT02783586

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultraplex
Description: A non-stimulating echogenic single-shot needle designed for regional analgesia under ultrasound guidance.
Study: NCT01748916

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Papaya
Description: Post-prandial study feeding 400-506 g papaya (1.6 mg beta-carotene, 2.1 mg beta-cryptoxanthin, 13 mg lycopene), 150 g yogurt (10% fat), and 45 g of fat free bread.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Papaya
Description: Post-prandial study feeding 400-506 g papaya (1.6 mg beta-carotene, 2.1 mg beta-cryptoxanthin, 13 mg lycopene), 150 g yogurt (10% fat), and 45 g of fat free bread.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Papaya
Description: Post-prandial study feeding 400-506 g papaya (1.6 mg beta-carotene, 2.1 mg beta-cryptoxanthin, 13 mg lycopene), 150 g yogurt (10% fat), and 45 g of fat free bread.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Papaya
Description: Post-prandial study feeding 400-506 g papaya (1.6 mg beta-carotene, 2.1 mg beta-cryptoxanthin, 13 mg lycopene), 150 g yogurt (10% fat), and 45 g of fat free bread.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Papaya
Description: Post-prandial study feeding 400-506 g papaya (1.6 mg beta-carotene, 2.1 mg beta-cryptoxanthin, 13 mg lycopene), 150 g yogurt (10% fat), and 45 g of fat free bread.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Papaya
Description: Post-prandial study feeding 400-506 g papaya (1.6 mg beta-carotene, 2.1 mg beta-cryptoxanthin, 13 mg lycopene), 150 g yogurt (10% fat), and 45 g of fat free bread.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Carrot
Description: Post-prandial study feeding 25-35 g carrot (= 1.6 mg beta-carotene), 150 g yogurt (10% fat), and 45 g of fat free bread.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Carrot
Description: Post-prandial study feeding 25-35 g carrot (= 1.6 mg beta-carotene), 150 g yogurt (10% fat), and 45 g of fat free bread.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Carrot
Description: Post-prandial study feeding 25-35 g carrot (= 1.6 mg beta-carotene), 150 g yogurt (10% fat), and 45 g of fat free bread.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Carrot
Description: Post-prandial study feeding 25-35 g carrot (= 1.6 mg beta-carotene), 150 g yogurt (10% fat), and 45 g of fat free bread.
Study: NCT00425516

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taxotere

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Study: NCT02791711

Intervention type: OTHER
Group type: OTHER
Intervention: High Flow Nasal Cannula
Description: Evaluation of the use of High Flow Nasal Cannula by biological markers, questionary of quality of use of HFNC by the physician, questionary of evaluation of adverse events with HFNC
Study: NCT02022410

Intervention type: OTHER
Intervention: CAS after primary and revision TKA
Description: CAS and RAPT
Study: NCT01748916

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Carrot
Description: Post-prandial study feeding 25-35 g carrot (= 1.6 mg beta-carotene), 150 g yogurt (10% fat), and 45 g of fat free bread.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Carrot
Description: Post-prandial study feeding 25-35 g carrot (= 1.6 mg beta-carotene), 150 g yogurt (10% fat), and 45 g of fat free bread.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tomato
Description: Post-prandial study feeding 256-396 g tomato (= 13 mg lycopene), 150 g yogurt (10% fat), and 45 g of fat free bread.
Study: NCT02720705

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: oral dexmedetomidine
Study: NCT01748916

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tomato
Description: Post-prandial study feeding 256-396 g tomato (= 13 mg lycopene), 150 g yogurt (10% fat), and 45 g of fat free bread.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tomato
Description: Post-prandial study feeding 256-396 g tomato (= 13 mg lycopene), 150 g yogurt (10% fat), and 45 g of fat free bread.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tomato
Description: Post-prandial study feeding 256-396 g tomato (= 13 mg lycopene), 150 g yogurt (10% fat), and 45 g of fat free bread.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tomato
Description: Post-prandial study feeding 256-396 g tomato (= 13 mg lycopene), 150 g yogurt (10% fat), and 45 g of fat free bread.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tomato
Description: Post-prandial study feeding 256-396 g tomato (= 13 mg lycopene), 150 g yogurt (10% fat), and 45 g of fat free bread.
Study: NCT02720705

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: oral dexmedetomidine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline
Description: 2ml 0.9% saline administered orally half an hour before induction of anesthesia
Study: NCT00557518

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alagebrium
Description: 200 mg bid

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: bid
Study: NCT01442207

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Placement of a Cervical Cerclage
Description: Surgical placement of a cervical cerclage

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Standard Expectant Management
Description: Participants assigned to the expectant management group will be followed by their doctor and managed per standard management which includes:~* Standard management for placenta previa.~* Hospital admission for vaginal bleeding/hemorrhage~* Antenatal corticosteroids \> 24w0d of gestation~* Tocolytic therapy per physician's discretion~* Magnesium sulfate for neuroprotection~* Fetal Heart Rate Monitoring~* Avoidance of digital examinations of the cervix~* Elective delivery no earlier than 36w0d gestation unless indicated (uncontrolled hemorrhage, imminent delivery, PROM \> 34 wks, worsening maternal or fetal condition )~* Fetal Fibronectin (fFN) test collected at the time of transvaginal Ultrasound.
Study: NCT02409888

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Enhancement Therapy
Description: The motivational enhancement therapy will be delivered according to the Project MATCH manual.
Study: NCT00318006

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: saline irrigation
Description: subjects were instructed in the technique of nasal lavage (irrigation group) or nasal saline spray (spray group) and were asked to do the assigned treatment twice daily for 8 weeks. They were provided with an 8-week supply of materials (Sinus Rinse irrigations from NeilMed Products Inc, and Deep Sea nasal saline spray distributed by Major Pharmaceuticals, Livonia, Michigan).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: saline spray
Description: subjects were instructed in the technique of nasal lavage (irrigation group) or nasal saline spray (spray group) and were asked to do the assigned treatment twice daily for 8 weeks. They were provided with an 8-week supply of materials (Sinus Rinse irrigations from NeilMed Products Inc, and Deep Sea nasal saline spray distributed by Major Pharmaceuticals, Livonia, Michigan).
Study: NCT04481256

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External beam radiotherapy
Description: External beam radiotherapy will be delivered to a total dose of 50.4 Gy in 28 fractions of 1.8 Gy, 5 fractions per week, starting the first day of the first cycle of chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bintrafusp alfa
Description: Bintrafusp alfa will be given i.v. every three weeks on day 1, 22, and 43 at a dose of 2400 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel 50 mg/m2 will be given intravenously (i.v.) on days 1, 8, 15, 22, 29 and 36.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin AUC = 2 will be given intravenously (i.v.) on days 1, 8, 15, 22, 29 and 36.
Study: NCT00892424

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Sorafenib doses will be 200mg twice daily orally for 28 days in level I, 400 mg in the morning and 200mg in the evening in level II, and 400mg twice daily orally for 28 days in level III . Radiotherapy will be started at day 8, patients will receive a total of 6 fractions over 2 weeks. Patients will be assessed weekly during treatment, 1 month post-tx, then at 3-month intervals for up to a year after tx, and then followed-up at 6-month intervals up to 3 years.
Study: NCT02258607

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Momelotinib (MMB)
Description: Momelotinib (MMB) tablet(s) administered orally once or twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Momelotinib (MMB)
Description: Momelotinib (MMB) tablet(s) administered orally once or twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Momelotinib (MMB)
Description: Momelotinib (MMB) tablet(s) administered orally once or twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Trametinib tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Trametinib tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Trametinib tablet administered orally once daily
Study: NCT01020773

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: spontaneous breathing trial

Intervention type: BEHAVIORAL
Group type: NO_INTERVENTION
Intervention: spontaneous breathing trial
Study: NCT04227652

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen administration
Description: Administration of ibuprofen, according to treatment recommendations - per orally, into the nasogastric tube, or in the form of a suppository

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen administration
Description: Administration of ibuprofen, according to treatment recommendations - per orally, into the nasogastric tube, or in the form of a suppository
Study: NCT03207815

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Tablet(s) administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prednisone
Description: Tablet(s) administered orally
Study: NCT01402570

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Glutathione
Description: glutathione is a dietary supplement and an antioxidant. Subjects will take 1000 mg per day for three month. Each capsule contains 500 mg glutathione.
Study: NCT02174692

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: One leg eccentric exercise: 7 sets of 10 repetitions at 80% 1 repetition maximum Contralateral leg concentric exercise: 7 sets of 10 repetitions at 80% 1 repetition maximum~2 mins rest between sets
Study: NCT02409888

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Description: The cognitive behavioral therapy will be delivered according to the Project MATCH manual.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FC Assessment
Description: FC Assessment study participants are exposed to quarterly assessments across broad domains of functioning.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IB Assessment
Description: IB Assessment study participants are exposed to semi-annual alcohol specific assessments